A Phase 3 interventional study of Emicizumab and Factor VIII (FVIII) in Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 39 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-11-16.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.
Among the 22 studies testing emicizumab in Hemophilia A, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 11 in phase 3, and was the 3rd registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Taiwan
Ages 12+ · Men only
Chulalongkorn University · Sites in Thailand
Ages 3–30 · Men only · Healthy volunteers
Bleeding and Clotting Disorders Institute Peoria, Illinois · Sites in United States
Ages 0–90
Indiana Hemophilia &Thrombosis Center, Inc. · Sites in United States
Ages 5–45 · Men only
Versiti Blood Health · Sites in United States
Ages 0–17
By country, each count listing its studies:
emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 13 · Phase 4 6
First in 2015; this study’s year is marked. 2 started in 2016.
This study's enrollment of 152 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 27 across the 22 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
25 studies in Hemophilia A by Hoffmann-La Roche: 5 open now, 8 under way, 4 of them phase 3. Of 15 finished, 12 (80%) have results posted.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2016, is one of 12 in phase 3, and was the 5th registered.
Hoffmann-La Roche’s Hemophilia A studies by the year they started, since 2012.
2 of the studies testing emicizumab in Hemophilia A that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05181618Hoffmann-La RocheA Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | 2026-11-19 |
| NCT05500807Bleeding and Clotting Disorders Institute Peoria, IllinoisEmicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing emicizumab in Hemophilia A, from their registry updates:
Among Hoffmann-La Roche’s 25 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who had received episodic treatment with FVIII prior to study entry were randomized to continue episodic FVIII treatment when they started the trial. After completing 24 weeks of no prophylaxis (i.e., episodic FVIII treatment) on study, then they were given the opportunity to switch to emicizumab prophylaxis of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 3 mg/kg emicizumab SC once every 2 weeks (Q2W). Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
Drug: Emicizumab · Drug: Factor VIII (FVIII)
Participants who had received episodic treatment with FVIII prior to study entry were randomized to receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram (mg/kg) subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 1.5 mg/kg emicizumab SC QW. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
Drug: Emicizumab · Drug: Factor VIII (FVIII)
Participants who had received episodic treatment with FVIII prior to study entry were randomized to receive emicizumab prophylaxis at a dose of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 3 mg/kg emicizumab SC once every 2 weeks (Q2W). Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
Drug: Emicizumab · Drug: Factor VIII (FVIII)
Participants who had received FVIII prophylaxis prior to study entry were enrolled to receive emicizumab prophylaxis at a dose of 3 mg/kg subcutaneously (SC) once per week (QW) for 4 weeks, followed by maintenance dosing of 1.5 mg/kg emicizumab SC QW. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant was given the option to choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study.
Drug: Emicizumab · Drug: Factor VIII (FVIII)
Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.
Also known as: Hemlibra, RO5534262, ACE910
FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
Annualized Bleeding Rate (ABR) for Treated Bleeds
The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a negative binomial (NB) regression model, which accounts for different follow-up times, with the number of bleeds as a function of randomization and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.
Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Annualized Bleeding Rate (ABR) for All Bleeds
The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.
Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Annualized Bleeding Rate (ABR) for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A "joint bleed" is defined as a bleed reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint; and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. It is considered a "treated joint bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.
Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.
Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds
The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A "target joint bleed" is defined as a bleed reported as a joint bleed into a target joint, defined as at least 3 bleeds into the same joint during the last 24 weeks prior to study entry. It is considered a "treated target joint bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.
Time frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With Factor VIII (FVIII) Prophylaxis (NISP)
This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.
Time frame: Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for Dnisp-FVIII Prophylaxis: 30.07 [5.0-45.1] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for Dnisp-Emicizumab Prophylaxis: 33.71 [20.1-48.6] weeks)
Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With FVIII Prophylaxis (NISP)
This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.
Time frame: Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for Dnisp-FVIII Prophylaxis: 30.07 [5.0-45.1] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for Dnisp-Emicizumab Prophylaxis: 33.71 [20.1-48.6] weeks)
Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)
This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.
Time frame: Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for A+Bnise-FVIII Episodic: 25.71 [15.4-40.9] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for A+Bnise-Emicizumab: 34.71 [24.1-50.6] weeks)
Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE)
This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.
Time frame: Efficacy periods: At least 24 weeks prior to study entry (median [min-max] for A+Bnise-FVIII Episodic: 25.71 [15.4-40.9] weeks); and From Baseline to at least 24 weeks on study (median [min-max] for A+Bnise-Emicizumab: 34.71 [24.1-50.6] weeks)
Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Physical Health Subscore for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25
The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health). The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.
Time frame: Baseline, Week 25
Haem-A-QoL Questionnaire Total Score for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25
The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Total Score is the average of all domain scores and it ranges from 0 to 100, with lower scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.
Time frame: Baseline, Week 25
European Quality of Life 5-Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score in the Randomized Population at Week 25
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.
Time frame: Baseline, Week 25
EQ-5D-5L Questionnaire Index Utility Score in the Randomized Population at Week 25
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single index utility score on a scale of 0 to 1, with higher scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.
Time frame: Baseline, Week 25
Hemophilia-Specific Quality of Life - Short Form (Haemo-QoL-SF) Questionnaire Score in Adolescent Participants (12 to 17 Years of Age) in the Randomized Population at Week 25
The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life.
Time frame: Week 25
Percentage of Participants With at Least One Adverse Event During the First 24 Weeks of the Study, Primary Analysis
The percentage of participants experiencing at least one adverse event, including all non-serious and serious adverse events, is reported here. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Percentage of Participants With at Least One Grade ≥3 Adverse Event During the First 24 Weeks of the Study, Primary Analysis
The World Health Organization (WHO) toxicity grading scale will be used for assessing adverse event severity. For adverse events that are not specifically listed in the WHO toxicity grading scale, a grade 3 adverse event is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a grade 4 adverse event is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Percentage of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment During the First 24 Weeks of the Study, Primary Analysis
At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs During the First 24 Weeks of the Study, Primary Analysis
The percentage of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings During the First 24 Weeks of the Study, Primary Analysis
Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Percentage of Participants With at Least One Adverse Event of Abnormal Laboratory Values During the First 24 Weeks of the Study, Primary Analysis
The percentage of participants with adverse events of abnormal laboratory values is reported here. An abnormal laboratory value is defined as a laboratory test result outside of the normal range for hematology or serum chemistries. It is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Percentage of Participants With at Least One Local Injection-Site Reaction During the First 24 Weeks of the Study, Primary Analysis
Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an "injection-site reaction" on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a "local injection-site reaction." At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Percentage of Participants With at Least One Thromboembolic Event During the First 24 Weeks of the Study, Primary Analysis
At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Percentage of Participants With at Least One Thrombotic Microangiopathy During the First 24 Weeks of the Study, Primary Analysis
At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Percentage of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction During the First 24 Weeks of the Study, Primary Analysis
At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
Time frame: From Baseline to at least 24 weeks (median [min-max] safety periods for Arm C (Control): 24.00 [14.4-25.0] weeks; Arm A: 30.00 [21.4-49.6] weeks; Arm B: 31.29 [24.4-50.6] weeks; Arm C (Emi): 7.57 [0.3-26.3] weeks; Arm D: 33.71 [18.4-49.6] weeks)
Safety Summary of the Percentage of Emicizumab-Treated Participants With at Least One Adverse Event During the Study
Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. For participants whose emicizumab dose was up-titrated and those who opted for a change in dosing regimen (after implementation of protocol v4), only AEs that occurred before either one of those events are included. Hypersens.= hypersensitivity; Mod. = modification
Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)
Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants
The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Emicizumab Participants
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 228.14 [7.3-288.3] weeks)
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Emicizumab Participants
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, 253-264, 265-276, and 277-288 weeks
Percentage of Participants With Anti-Emicizumab Antibodies at Any Time Post-Baseline During the Study
A validated enzyme-linked immunosorbent assay (ELISA) method was used to analyze the levels of anti-drug antibodies (ADAs) against emicizumab in plasma. A sample was considered positive for anti-emicizumab antibodies if the test result reached or exceeded a pre-determined threshold. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample.
Time frame: From Baseline to discontinuation from study (median [min-max] observation period for all emicizumab participants: 262.3 [14.4-288.3] weeks)
Percentage of Participants With De Novo Development of Factor VIII (FVIII) Inhibitors
Levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold.
Time frame: From Baseline to discontinuation from study (median [min-max] observation period for all emicizumab participants: 262.3 [14.4-288.3] weeks)
Trough Plasma Concentration (Ctrough) of Emicizumab
Trough plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) was 100 nanograms per milliliter (ng/mL). Because participants in Arm C (Control) switched from no prophylaxis to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm C (Emi) are expressed relative to first emicizumab dose.
Time frame: Predose at Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181, 193, 205, 217, 229, 241, 253, 265, and 277
| Milestone | Arm C (Control): No Prophylaxis, Then Emicizumab | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|
| Started | 18 | 36 | 35 | 63 |
| Completed first 24 weeks of treatment | 16 | 35 | 34 | 63 |
| Emicizumab dose was up-titrated | 0 | 1 | 1 | 7 |
| Opted to change emicizumab dosing regimen | 1 | 3 | 1 | 1 |
| Completed | 17 | 34 | 34 | 63 |
| Not completed | 1 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 |
The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a negative binomial (NB) regression model, which accounts for different follow-up times, with the number of bleeds as a function of randomization and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.
| treated bleed rate per year | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|
| Annualized Bleeding Rate (ABR) for Treated Bleeds | 38.2 (22.86 to 63.76) | 1.5 (0.89 to 2.47) | 1.3 (0.75 to 2.25) | 1.6 (1.07 to 2.44) |
The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.
| all bleed rate per year | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|
| Annualized Bleeding Rate (ABR) for All Bleeds | 47.6 (28.45 to 79.59) | 2.5 (1.63 to 3.90) | 2.6 (1.63 to 4.29) | 3.3 (2.22 to 4.83) |
The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A "joint bleed" is defined as a bleed reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint; and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. It is considered a "treated joint bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.
| treated joint bleed rate per year | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|
| Annualized Bleeding Rate (ABR) for Treated Joint Bleeds | 26.5 (14.67 to 47.79) | 1.1 (0.59 to 1.89) | 0.9 (0.44 to 1.67) | 1.2 (0.70 to 2.01) |
The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.
| treated spontaneous bleed rate per year | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|
| Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds | 15.6 (7.60 to 31.91) | 1.0 (0.48 to 1.91) | 0.3 (0.11 to 0.75) | 0.5 (0.23 to 0.94) |
The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (\<9 or ≥9) in the last 24 weeks prior to study entry as a stratification factor. A "target joint bleed" is defined as a bleed reported as a joint bleed into a target joint, defined as at least 3 bleeds into the same joint during the last 24 weeks prior to study entry. It is considered a "treated target joint bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed". Bleeds due to surgery/procedure are excluded.
| treated target joint bleed rate per year | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|
| Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds | 13.0 (5.22 to 32.33) | 0.6 (0.28 to 1.42) | 0.7 (0.27 to 1.64) | 0.6 (0.26 to 1.53) |
This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.
| treated bleed rate per year | Dnisp: Pre-Study FVIII Prophylaxis in NIS BH29768 | Dnisp: Emicizumab Prophylaxis (Pre-Study FVIII Prophylaxis) |
|---|---|---|
| Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With Factor VIII (FVIII) Prophylaxis (NISP) | 4.8 (3.22 to 7.09) | 1.5 (0.98 to 2.33) |
This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.
| all bleed rate per year | Dnisp: Pre-Study FVIII Prophylaxis in NIS BH29768 | Dnisp: Emicizumab Prophylaxis (Pre-Study FVIII Prophylaxis) |
|---|---|---|
| Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With FVIII Prophylaxis (NISP) | 8.9 (5.72 to 13.87) | 3.3 (2.17 to 5.06) |
This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.
| treated bleed rate per year | A+Bnise: Pre-Study Episodic FVIII in NIS BH29768 | A+Bnise: Emicizumab Prophylaxis (Pre-study Episodic FVIII) |
|---|---|---|
| Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE) | 34.4 (27.45 to 43.14) | 1.0 (0.43 to 2.54) |
This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. "All bleeds" comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.
| all bleed rate per year | A+Bnise: Pre-Study Episodic FVIII in NIS BH29768 | A+Bnise: Emicizumab Prophylaxis (Pre-study Episodic FVIII) |
|---|---|---|
| Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE) | 39.6 (31.94 to 49.04) | 1.6 (0.85 to 2.92) |
The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health). The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.
| units on a scale | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W |
|---|---|---|---|
| Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Physical Health Subscore for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25 | 44.32 ± 17.15 | 31.81 ± 27.86 | 28.35 ± 25.57 |
The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Total Score is the average of all domain scores and it ranges from 0 to 100, with lower scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.
| units on a scale | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W |
|---|---|---|---|
| Haem-A-QoL Questionnaire Total Score for Adult Participants (≥18 Years of Age) in the Randomized Population at Week 25 | 29.95 ± 13.56 | 24.04 ± 15.26 | 21.39 ± 12.64 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.
| units on a scale | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W |
|---|---|---|---|
| European Quality of Life 5-Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score in the Randomized Population at Week 25 | 72.57 ± 8.20 | 76.61 ± 20.99 | 81.72 ± 15.55 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single index utility score on a scale of 0 to 1, with higher scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.
| units on a scale | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W |
|---|---|---|---|
| EQ-5D-5L Questionnaire Index Utility Score in the Randomized Population at Week 25 | 0.63 ± 0.20 | 0.76 ± 0.24 | 0.76 ± 0.18 |
The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life.
No measurements were reported for this outcome.
The percentage of participants experiencing at least one adverse event, including all non-serious and serious adverse events, is reported here. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event During the First 24 Weeks of the Study, Primary Analysis | 33.3 | 94.4 | 85.7 | 50.0 | 87.3 |
The World Health Organization (WHO) toxicity grading scale will be used for assessing adverse event severity. For adverse events that are not specifically listed in the WHO toxicity grading scale, a grade 3 adverse event is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a grade 4 adverse event is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Grade ≥3 Adverse Event During the First 24 Weeks of the Study, Primary Analysis | 5.6 | 8.3 | 11.4 | 0 | 9.3 |
At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment During the First 24 Weeks of the Study, Primary Analysis | 0 | 0 | 2.9 | 0 | 0 |
The percentage of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs During the First 24 Weeks of the Study, Primary Analysis | 0 | 0 | 0 | 0 | 0 |
Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings During the First 24 Weeks of the Study, Primary Analysis | 0 | 0 | 0 | 0 | 0 |
The percentage of participants with adverse events of abnormal laboratory values is reported here. An abnormal laboratory value is defined as a laboratory test result outside of the normal range for hematology or serum chemistries. It is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event of Abnormal Laboratory Values During the First 24 Weeks of the Study, Primary Analysis | 0 | 5.6 | 17.1 | 6.3 | 4.8 |
Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an "injection-site reaction" on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a "local injection-site reaction." At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Local Injection-Site Reaction During the First 24 Weeks of the Study, Primary Analysis | 0 | 25.0 | 20.0 | 12.5 | 33.3 |
At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Thromboembolic Event During the First 24 Weeks of the Study, Primary Analysis | 0 | 0 | 0 | 0 | 0 |
At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Thrombotic Microangiopathy During the First 24 Weeks of the Study, Primary Analysis | 0 | 0 | 0 | 0 | 0 |
At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of at least 24 weeks.
| percentage of participants | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis up to PCD) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| Percentage of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction During the First 24 Weeks of the Study, Primary Analysis | 0 | 0 | 0 | 0 | 0 |
Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. For participants whose emicizumab dose was up-titrated and those who opted for a change in dosing regimen (after implementation of protocol v4), only AEs that occurred before either one of those events are included. Hypersens.= hypersensitivity; Mod. = modification
| percentage of participants | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | All Emicizumab Participants |
|---|---|---|---|---|---|
| Any Adverse Event (AE) | 100.0 | 97.1 | 88.2 | 100.0 | 98.0 |
| AE with Fatal Outcome | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Serious AE | 27.8 | 22.9 | 5.9 | 25.4 | 23.2 |
| AE Leading to Withdrawal from Treatment | 0.0 | 2.9 | 0.0 | 0.0 | 0.7 |
| AE Leading to Dose Mod./Interruption | 2.8 | 0.0 | 0.0 | 1.6 | 1.3 |
| Grade ≥3 AE | 36.1 | 28.6 | 5.9 | 20.6 | 24.5 |
| Related AE | 30.6 | 34.3 | 23.5 | 47.6 | 37.7 |
| Local Injection Site Reaction | 27.8 | 22.9 | 23.5 | 39.7 | 31.1 |
| Systemic Hypersens./Anaphylac(tic/toid) Reaction | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Thromboembolic Event (TE) | 0.0 | 2.9 | 0.0 | 1.6 | 1.3 |
| Thrombotic Microangiopathy (TMA) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
| bleeds per year | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | All Emicizumab Participants |
|---|---|---|---|---|---|
| Treated Bleeds | 0.8 (0.48 to 1.29) | 0.7 (0.40 to 1.08) | 1.2 (0.47 to 3.19) | 1.5 (1.02 to 2.34) | 1.2 (0.92 to 1.56) |
| All Bleeds | 1.1 (0.72 to 1.66) | 1.1 (0.73 to 1.73) | 2.2 (1.16 to 4.15) | 2.4 (1.68 to 3.43) | 1.8 (1.46 to 2.29) |
| Treated Spontaneous Bleeds | 0.5 (0.23 to 1.03) | 0.2 (0.10 to 0.45) | 0.4 (0.12 to 1.35) | 0.5 (0.30 to 0.78) | 0.4 (0.29 to 0.58) |
| Treated Joint Bleeds | 0.4 (0.24 to 0.73) | 0.4 (0.21 to 0.68) | 0.7 (0.25 to 1.66) | 1.0 (0.60 to 1.76) | 0.7 (0.53 to 1.00) |
| Treated Target Joint Bleeds | 0.2 (0.11 to 0.43) | 0.2 (0.08 to 0.39) | 0.4 (0.13 to 1.31) | 0.6 (0.26 to 1.42) | 0.4 (0.29 to 0.66) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
| bleeds per year | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | All Emicizumab Participants |
|---|---|---|---|---|---|
| Treated Bleeds | 1.2 (0.04 to 5.83) | 0.8 (0.01 to 5.23) | 1.2 (0.05 to 5.95) | 1.7 (0.15 to 6.69) | 1.3 (0.07 to 6.07) |
| All Bleeds | 1.4 (0.09 to 6.29) | 1.3 (0.07 to 6.10) | 2.2 (0.32 to 7.58) | 2.6 (0.45 to 8.15) | 2.0 (0.23 to 7.19) |
| Treated Spontaneous Bleeds | 0.7 (0.00 to 4.97) | 0.3 (0.00 to 4.22) | 0.4 (0.00 to 4.48) | 0.6 (0.00 to 4.81) | 0.5 (0.00 to 4.68) |
| Treated Joint Bleeds | 0.6 (0.00 to 4.94) | 0.5 (0.00 to 4.64) | 0.6 (0.00 to 4.95) | 1.1 (0.04 to 5.78) | 0.8 (0.01 to 5.23) |
| Treated Target Joint Bleeds | 0.4 (0.00 to 4.54) | 0.3 (0.00 to 4.28) | 0.4 (0.00 to 4.50) | 0.6 (0.00 to 4.92) | 0.5 (0.00 to 4.64) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
| bleeds per year | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | All Emicizumab Participants |
|---|---|---|---|---|---|
| Treated Bleeds | 0.4 (0.00 to 1.28) | 0.4 (0.00 to 1.06) | 0.0 (0.00 to 2.48) | 0.5 (0.00 to 1.07) | 0.4 (0.00 to 1.15) |
| All Bleeds | 0.5 (0.09 to 1.77) | 0.8 (0.23 to 1.92) | 1.6 (0.20 to 3.8) | 1.0 (0.38 to 2.70) | 1.0 (0.19 to 2.37) |
| Treated Spontaneous Bleeds | 0.0 (0.00 to 0.51) | 0.0 (0.00 to 0.23) | 0.0 (0.00 to 0.65) | 0.0 (0.00 to 0.48) | 0.0 (0.00 to 0.40) |
| Treated Joint Bleeds | 0.2 (0.00 to 0.89) | 0.2 (0.00 to 0.49) | 0.0 (0.00 to 1.09) | 0.0 (0.00 to 0.59) | 0.2 (0.00 to 0.72) |
| Treated Target Joint Bleeds | 0.1 (0.00 to 0.55) | 0.0 (0.00 to 0.37) | 0.0 (0.00 to 0.81) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.38) |
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| Treated bleeds per year | All Emicizumab Participants |
|---|---|
| 1 to 12 Weeks | 1.9 (0.21 to 7.04) |
| 13 to 24 Weeks | 1.9 (0.20 to 6.99) |
| 25 to 36 Weeks | 1.0 (0.02 to 5.57) |
| 37 to 48 Weeks | 0.9 (0.01 to 5.35) |
| 49 to 60 Weeks | 1.0 (0.02 to 5.54) |
| 61 to 72 Weeks | 1.1 (0.04 to 5.72) |
| 73 to 84 Weeks | 0.7 (0.01 to 5.12) |
| 85 to 96 Weeks | 1.1 (0.03 to 5.68) |
| 97 to 108 Weeks | 0.9 (0.01 to 5.32) |
| 109 to 120 Weeks | 0.6 (0.00 to 4.83) |
| 121 to 132 Weeks | 0.5 (0.00 to 4.72) |
| 133 to 144 Weeks | 1.1 (0.03 to 5.68) |
| 145 to 156 Weeks | 1.1 (0.03 to 5.70) |
| 157 to 168 Weeks | 1.1 (0.04 to 5.78) |
| 169 to 180 Weeks | 1.3 (0.06 to 6.05) |
| 181 to 192 Weeks | 1.0 (0.02 to 5.56) |
| 193 to 204 Weeks | 1.6 (0.13 to 6.57) |
| 205 to 216 Weeks | 0.8 (0.01 to 5.15) |
| 217 to 228 Weeks | 0.5 (0.00 to 4.59) |
| 229 to 240 Weeks | 0.8 (0.01 to 5.30) |
| 241 to 252 Weeks | 0.3 (0.00 to 4.21) |
| 253 to 264 Weeks | 0.5 (0.00 to 4.72) |
| 265 to 276 Weeks | 0.2 (0.00 to 4.09) |
| 277 to 288 Weeks | 0.0 (NA to 3.69) |
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| Treated bleeds per year | All Emicizumab Participants |
|---|---|
| 1 to 12 Weeks | 0.0 (0.00 to 4.35) |
| 13 to 24 Weeks | 0.0 (0.00 to 2.17) |
| 25 to 36 Weeks | 0.0 (0.00 to 0.00) |
| 37 to 48 Weeks | 0.0 (0.00 to 0.00) |
| 49 to 60 Weeks | 0.0 (0.00 to 0.00) |
| 61 to 72 Weeks | 0.0 (0.00 to 0.00) |
| 73 to 84 Weeks | 0.0 (0.00 to 0.00) |
| 85 to 96 Weeks | 0.0 (0.00 to 0.00) |
| 97 to 108 Weeks | 0.0 (0.00 to 0.00) |
| 109 to 120 Weeks | 0.0 (0.00 to 0.00) |
| 121 to 132 Weeks | 0.0 (0.00 to 0.00) |
| 133 to 144 Weeks | 0.0 (0.00 to 0.00) |
| 145 to 156 Weeks | 0.0 (0.00 to 0.00) |
| 157 to 168 Weeks | 0.0 (0.00 to 0.00) |
| 169 to 180 Weeks | 0.0 (0.00 to 0.00) |
| 181 to 192 Weeks | 0.0 (0.00 to 0.00) |
| 193 to 204 Weeks | 0.0 (0.00 to 0.00) |
| 205 to 216 Weeks | 0.0 (0.00 to 0.00) |
| 217 to 228 Weeks | 0.0 (0.00 to 0.00) |
| 229 to 240 Weeks | 0.0 (0.00 to 0.00) |
| 241 to 252 Weeks | 0.0 (0.00 to 0.00) |
| 253 to 264 Weeks | 0.0 (0.00 to 0.00) |
| 265 to 276 Weeks | 0.0 (0.00 to 0.00) |
| 277 to 288 Weeks | 0.0 (0.00 to 0.00) |
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| All bleeds per year | All Emicizumab Participants |
|---|---|
| 1 to 12 Weeks | 3.8 (0.97 to 9.91) |
| 13 to 24 Weeks | 2.8 (0.53 to 8.45) |
| 25 to 36 Weeks | 1.8 (0.17 to 6.83) |
| 37 to 48 Weeks | 1.4 (0.10 to 6.33) |
| 49 to 60 Weeks | 1.5 (0.10 to 6.37) |
| 61 to 72 Weeks | 1.6 (0.14 to 6.66) |
| 73 to 84 Weeks | 1.2 (0.05 to 5.88) |
| 85 to 96 Weeks | 1.4 (0.09 to 6.30) |
| 97 to 108 Weeks | 1.3 (0.06 to 6.02) |
| 109 to 120 Weeks | 0.8 (0.01 to 5.21) |
| 121 to 132 Weeks | 0.8 (0.01 to 5.20) |
| 133 to 144 Weeks | 1.2 (0.04 to 5.84) |
| 145 to 156 Weeks | 1.3 (0.06 to 6.02) |
| 157 to 168 Weeks | 1.4 (0.09 to 6.28) |
| 169 to 180 Weeks | 1.7 (0.15 to 6.72) |
| 181 to 192 Weeks | 1.4 (0.08 to 6.19) |
| 193 to 204 Weeks | 1.7 (0.16 to 6.74) |
| 205 to 216 Weeks | 1.1 (0.04 to 5.72) |
| 217 to 228 Weeks | 0.6 (0.00 to 4.91) |
| 229 to 240 Weeks | 0.9 (0.02 to 5.41) |
| 241 to 252 Weeks | 0.4 (0.00 to 4.47) |
| 253 to 264 Weeks | 0.6 (0.00 to 4.86) |
| 265 to 276 Weeks | 0.2 (0.00 to 4.09) |
| 277 to 288 Weeks | 0.0 (NA to 3.69) |
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| All bleeds per year | All Emicizumab Participants |
|---|---|
| 1 to 12 Weeks | 0.0 (0.00 to 4.35) |
| 13 to 24 Weeks | 0.0 (0.00 to 4.35) |
| 25 to 36 Weeks | 0.0 (0.00 to 4.35) |
| 37 to 48 Weeks | 0.0 (0.00 to 0.00) |
| 49 to 60 Weeks | 0.0 (0.00 to 0.00) |
| 61 to 72 Weeks | 0.0 (0.00 to 0.00) |
| 73 to 84 Weeks | 0.0 (0.00 to 0.00) |
| 85 to 96 Weeks | 0.0 (0.00 to 0.00) |
| 97 to 108 Weeks | 0.0 (0.00 to 0.00) |
| 109 to 120 Weeks | 0.0 (0.00 to 0.00) |
| 121 to 132 Weeks | 0.0 (0.00 to 0.00) |
| 133 to 144 Weeks | 0.0 (0.00 to 0.00) |
| 145 to 156 Weeks | 0.0 (0.00 to 0.00) |
| 157 to 168 Weeks | 0.0 (0.00 to 0.00) |
| 169 to 180 Weeks | 0.0 (0.00 to 0.00) |
| 181 to 192 Weeks | 0.0 (0.00 to 0.00) |
| 193 to 204 Weeks | 0.0 (0.00 to 0.00) |
| 205 to 216 Weeks | 0.0 (0.00 to 0.00) |
| 217 to 228 Weeks | 0.0 (0.00 to 0.00) |
| 229 to 240 Weeks | 0.0 (0.00 to 0.00) |
| 241 to 252 Weeks | 0.0 (0.00 to 0.00) |
| 253 to 264 Weeks | 0.0 (0.00 to 0.00) |
| 265 to 276 Weeks | 0.0 (0.00 to 0.00) |
| 277 to 288 Weeks | 0.0 (0.00 to 0.00) |
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| Treated spontaneous bleeds per year | All Emicizumab Participants |
|---|---|
| 1 to 12 Weeks | 0.7 (0.00 to 4.98) |
| 13 to 24 Weeks | 0.7 (0.00 to 5.00) |
| 25 to 36 Weeks | 0.3 (0.00 to 4.30) |
| 37 to 48 Weeks | 0.4 (0.00 to 4.53) |
| 49 to 60 Weeks | 0.5 (0.00 to 4.60) |
| 61 to 72 Weeks | 0.3 (0.00 to 4.25) |
| 73 to 84 Weeks | 0.1 (0.00 to 3.95) |
| 85 to 96 Weeks | 0.4 (0.00 to 4.48) |
| 97 to 108 Weeks | 0.2 (0.00 to 4.14) |
| 109 to 120 Weeks | 0.2 (0.00 to 4.03) |
| 121 to 132 Weeks | 0.1 (0.00 to 3.96) |
| 133 to 144 Weeks | 0.6 (0.00 to 4.78) |
| 145 to 156 Weeks | 0.6 (0.00 to 4.87) |
| 157 to 168 Weeks | 0.2 (0.00 to 4.09) |
| 169 to 180 Weeks | 0.4 (0.00 to 4.50) |
| 181 to 192 Weeks | 0.2 (0.00 to 4.01) |
| 193 to 204 Weeks | 0.1 (0.00 to 3.80) |
| 205 to 216 Weeks | 0.3 (0.00 to 4.24) |
| 217 to 228 Weeks | 0.1 (0.00 to 3.81) |
| 229 to 240 Weeks | 0.1 (0.00 to 3.94) |
| 241 to 252 Weeks | 0.1 (0.00 to 3.82) |
| 253 to 264 Weeks | 0.3 (0.00 to 4.29) |
| 265 to 276 Weeks | 0.2 (0.00 to 4.09) |
| 277 to 288 Weeks | 0.0 (NA to 3.69) |
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v4), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| Treated spontaneous bleeds per year | All Emicizumab Participants |
|---|---|
| 1 to 12 Weeks | 0.0 (0.00 to 0.00) |
| 13 to 24 Weeks | 0.0 (0.00 to 0.00) |
| 25 to 36 Weeks | 0.0 (0.00 to 0.00) |
| 37 to 48 Weeks | 0.0 (0.00 to 0.00) |
| 49 to 60 Weeks | 0.0 (0.00 to 0.00) |
| 61 to 72 Weeks | 0.0 (0.00 to 0.00) |
| 73 to 84 Weeks | 0.0 (0.00 to 0.00) |
| 85 to 96 Weeks | 0.0 (0.00 to 0.00) |
| 97 to 108 Weeks | 0.0 (0.00 to 0.00) |
| 109 to 120 Weeks | 0.0 (0.00 to 0.00) |
| 121 to 132 Weeks | 0.0 (0.00 to 0.00) |
| 133 to 144 Weeks | 0.0 (0.00 to 0.00) |
| 145 to 156 Weeks | 0.0 (0.00 to 0.00) |
| 157 to 168 Weeks | 0.0 (0.00 to 0.00) |
| 169 to 180 Weeks | 0.0 (0.00 to 0.00) |
| 181 to 192 Weeks | 0.0 (0.00 to 0.00) |
| 193 to 204 Weeks | 0.0 (0.00 to 0.00) |
| 205 to 216 Weeks | 0.0 (0.00 to 0.00) |
| 217 to 228 Weeks | 0.0 (0.00 to 0.00) |
| 229 to 240 Weeks | 0.0 (0.00 to 0.00) |
| 241 to 252 Weeks | 0.0 (0.00 to 0.00) |
| 253 to 264 Weeks | 0.0 (0.00 to 0.00) |
| 265 to 276 Weeks | 0.0 (0.00 to 0.00) |
| 277 to 288 Weeks | 0.0 (0.00 to 0.00) |
A validated enzyme-linked immunosorbent assay (ELISA) method was used to analyze the levels of anti-drug antibodies (ADAs) against emicizumab in plasma. A sample was considered positive for anti-emicizumab antibodies if the test result reached or exceeded a pre-determined threshold. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample.
| percentage of participants | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | All Emicizumab Participants |
|---|---|---|---|---|---|
| Total ADA Positive (Boosted+Induced) | 8.3 | 5.7 | 0.0 | 1.6 | 4.0 |
| ADA Positive (Treatment Boosted) | 0.0 | 2.9 | 0.0 | 0.0 | 0.7 |
| ADA Positive (Treatment Induced) | 8.3 | 2.9 | 0.0 | 1.6 | 3.3 |
Levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold.
| percentage of participants | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | All Emicizumab Participants |
|---|---|---|---|---|---|
| Percentage of Participants With De Novo Development of Factor VIII (FVIII) Inhibitors | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Trough plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) was 100 nanograms per milliliter (ng/mL). Because participants in Arm C (Control) switched from no prophylaxis to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm C (Emi) are expressed relative to first emicizumab dose.
| micrograms per milliliter (μg/mL) | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | Arms A and D: Emicizumab 1.5 mg/kg QW | Arms B and C (Emi): Emicizumab 3 mg/kg Q2W |
|---|---|---|---|---|---|---|
| Week 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Week 2 | 16.3 ± 6.1 | 16.8 ± 5.9 | 19.6 ± 8.2 | 17.3 ± 5.4 | 16.9 ± 5.7 | 17.7 ± 6.8 |
| Week 3 | 29.1 ± 9.3 | 29.2 ± 6.5 | 33.0 ± 12.6 | 30.5 ± 8.7 | 30.0 ± 8.9 | 30.5 ± 9.0 |
| Week 4 | 41.9 ± 11.8 | 41.4 ± 9.7 | 47.9 ± 15.0 | 42.4 ± 9.4 | 42.2 ± 10.3 | 43.6 ± 11.9 |
| Week 5 | 48.0 ± 13.7 | 48.8 ± 12.3 | 59.6 ± 20.7 | 54.5 ± 12.5 | 52.2 ± 13.2 | 52.4 ± 16.2 |
| Week 7 | 47.9 ± 16.1 | 48.4 ± 11.4 | 55.2 ± 16.2 | 52.4 ± 13.3 | 50.9 ± 14.4 | 50.7 ± 13.5 |
| Week 9 | 49.0 ± 16.4 | 46.4 ± 14.1 | 53.1 ± 15.7 | 55.1 ± 16.1 | 53.0 ± 16.4 | 48.7 ± 14.9 |
| Week 13 | 48.7 ± 18.3 | 47.6 ± 16.0 | 47.9 ± 18.1 | 55.0 ± 15.9 | 52.8 ± 16.9 | 47.7 ± 16.5 |
| Week 17 | 54.3 ± 24.0 | 48.9 ± 17.7 | 43.4 ± 16.2 | 55.0 ± 16.5 | 54.7 ± 19.3 | 47.0 ± 17.2 |
| Week 21 | 50.7 ± 20.2 | 47.3 ± 15.5 | 45.6 ± 18.8 | 55.1 ± 16.2 | 53.6 ± 17.7 | 46.7 ± 16.4 |
| Week 25 | 50.5 ± 21.7 | 47.6 ± 18.9 | 51.8 ± 23.4 | 54.8 ± 16.8 | 53.3 ± 18.7 | 49.0 ± 20.4 |
| Week 33 | 56.3 ± 25.3 | 52.9 ± 22.4 | 52.0 ± 21.3 | 59.1 ± 18.5 | 58.1 ± 20.9 | 52.6 ± 21.9 |
| Week 41 | 54.8 ± 24.2 | 48.4 ± 18.8 | 50.7 ± 24.4 | 59.6 ± 21.4 | 57.9 ± 22.4 | 49.2 ± 20.6 |
| Week 49 | 55.4 ± 22.9 | 52.2 ± 20.2 | 54.3 ± 21.3 | 60.2 ± 19.9 | 58.5 ± 21.0 | 52.9 ± 20.4 |
| Week 61 | 55.3 ± 21.4 | 52.0 ± 21.1 | 52.5 ± 19.8 | 61.1 ± 22.5 | 59.1 ± 22.1 | 52.2 ± 20.5 |
| Week 73 | 54.4 ± 21.5 | 51.6 ± 21.3 | 47.8 ± 18.4 | 58.5 ± 19.2 | 57.1 ± 20.0 | 50.4 ± 20.3 |
| Week 85 | 48.8 ± 17.4 | 46.4 ± 20.4 | 47.7 ± 17.9 | 56.7 ± 18.5 | 53.8 ± 18.5 | 46.8 ± 19.5 |
| Week 97 | 52.6 ± 20.0 | 50.9 ± 21.0 | 51.7 ± 28.3 | 58.5 ± 18.7 | 56.3 ± 19.3 | 51.1 ± 22.9 |
| Week 109 | 53.9 ± 19.2 | 52.3 ± 19.5 | 46.4 ± 27.0 | 59.0 ± 19.1 | 57.0 ± 19.1 | 50.5 ± 21.7 |
| Week 121 | 58.8 ± 21.1 | 55.0 ± 22.0 | 50.0 ± 25.2 | 57.1 ± 18.2 | 57.7 ± 19.2 | 53.5 ± 22.7 |
| Week 133 | 55.3 ± 26.0 | 54.7 ± 18.5 | 54.6 ± 26.9 | 59.3 ± 19.2 | 57.7 ± 22.1 | 54.7 ± 20.9 |
| Week 145 | 54.1 ± 23.7 | 51.3 ± 17.7 | 44.8 ± 11.6 | 55.7 ± 20.4 | 55.0 ± 21.6 | 49.9 ± 16.6 |
| Week 157 | 57.6 ± 27.8 | 52.2 ± 21.4 | 46.8 ± 24.0 | 55.9 ± 23.7 | 56.6 ± 25.1 | 50.6 ± 21.9 |
| Week 169 | 53.9 ± 21.8 | 50.3 ± 19.6 | 45.8 ± 20.6 | 56.4 ± 18.0 | 55.3 ± 19.4 | 48.8 ± 19.6 |
| Week 181 | 59.8 ± 24.8 | 48.8 ± 22.1 | 43.5 ± 26.2 | 57.5 ± 21.3 | 58.6 ± 22.7 | 46.5 ± 23.4 |
| Week 193 | 53.9 ± 21.0 | 52.4 ± 24.6 | 42.1 ± 19.1 | 60.5 ± 19.6 | 57.5 ± 20.2 | 49.5 ± 23.3 |
| Week 205 | 53.5 ± 20.8 | 51.9 ± 22.4 | 54.2 ± 31.1 | 58.6 ± 24.1 | 56.4 ± 22.6 | 52.6 ± 24.6 |
| Week 217 | 54.4 ± 20.8 | 55.0 ± 20.6 | 50.8 ± 26.1 | 60.8 ± 23.2 | 58.3 ± 22.2 | 53.6 ± 22.1 |
| Week 229 | 54.9 ± 20.9 | 47.9 ± 18.9 | 53.5 ± 30.4 | 54.4 ± 19.3 | 54.6 ± 19.7 | 49.8 ± 23.1 |
| Week 241 | 51.9 ± 19.3 | 50.2 ± 16.8 | 52.0 ± 36.1 | 60.1 ± 23.3 | 56.8 ± 21.9 | 50.6 ± 22.2 |
| Week 253 | 58.6 ± 28.7 | 46.5 ± 17.8 | 40.3 ± 43.9 | 58.4 ± 24.7 | 58.5 ± 26.0 | 45.2 ± 23.9 |
| Week 265 | 58.7 ± 25.8 | 47.3 ± 14.5 | — | 60.0 ± 23.9 | 59.5 ± 24.2 | 47.3 ± 14.5 |
| Week 277 | 71.9 ± 34.2 | 49.0 ± 16.2 | — | 61.3 ± 17.2 | 69.2 ± 30.1 | 49.0 ± 16.2 |
Collected over Total observation time for all participants: From enrollment until study completion (median [min-max] 262.3 [14.4-288.3] weeks); Arm C (Control): From enrollment to 24 weeks on no prophylaxis (median [min-max]: 24.00 [14.4-25.0] weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm C (Control): No Prophylaxis | 0/18 (0%) | 1/18 (5.6%) | 5/18 (27.8%) |
| Arm A: Emicizumab 1.5 mg/kg QW | 0/36 (0%) | 10/36 (27.8%) | 35/36 (97.2%) |
| Arm B: Emicizumab 3 mg/kg Q2W | 0/35 (0%) | 8/35 (22.9%) | 33/35 (94.3%) |
| Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | 0/17 (0%) | 1/17 (5.9%) | 15/17 (88.2%) |
| Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | 0/63 (0%) | 16/63 (25.4%) | 61/63 (96.8%) |
| Event | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| GINGIVAL ABSCESSInfections and infestations | 0/18 | 0/36 | 0/35 | 1/17 | 0/63 |
| HAEMATOMAVascular disorders | 1/18 | 1/36 | 0/35 | 0/17 | 1/63 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/18 | 0/36 | 1/35 | 0/17 | 0/63 |
| ARRHYTHMIACardiac disorders | 0/18 | 0/36 | 1/35 | 0/17 | 0/63 |
| ATRIAL FLUTTERCardiac disorders | 0/18 | 0/36 | 1/35 | 0/17 | 0/63 |
| HYPERPARATHYROIDISMEndocrine disorders | 0/18 | 0/36 | 1/35 | 0/17 | 0/63 |
| MELAENAGastrointestinal disorders | 0/18 | 1/36 | 1/35 | 0/17 | 0/63 |
| UPPER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 0/18 | 0/36 | 1/35 | 0/17 | 0/63 |
| FEMUR FRACTUREInjury, poisoning and procedural complications | 0/18 | 0/36 | 1/35 | 0/17 | 0/63 |
| TENDON RUPTUREInjury, poisoning and procedural complications | 0/18 | 0/36 | 1/35 | 0/17 | 0/63 |
| Event | Arm C (Control): No Prophylaxis | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm C (Emi): Emicizumab 3 mg/kg Q2W (Switch From No Prophylaxis) | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) |
|---|---|---|---|---|---|
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 1/18 | 16/36 | 11/35 | 3/17 | 25/63 |
| INJECTION SITE REACTIONGeneral disorders | 0/18 | 10/36 | 8/35 | 4/17 | 24/63 |
| NASOPHARYNGITISInfections and infestations | 1/18 | 9/36 | 8/35 | 3/17 | 20/63 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/18 | 8/36 | 6/35 | 3/17 | 14/63 |
| HEADACHENervous system disorders | 1/18 | 7/36 | 7/35 | 2/17 | 14/63 |
| INFLUENZAInfections and infestations | 0/18 | 7/36 | 4/35 | 2/17 | 9/63 |
| ABDOMINAL PAINGastrointestinal disorders | 0/18 | 3/36 | 0/35 | 3/17 | 2/63 |
| BACK PAINMusculoskeletal and connective tissue disorders | 1/18 | 6/36 | 3/35 | 2/17 | 8/63 |
| LIGAMENT SPRAINInjury, poisoning and procedural complications | 0/18 | 2/36 | 1/35 | 1/17 | 10/63 |
| DIARRHOEAGastrointestinal disorders | 1/18 | 4/36 | 5/35 | 2/17 | 6/63 |
| Age, Continuous(years) | Arm C (Control): No Prophylaxis, Then Emicizumab | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | Total |
|---|---|---|---|---|---|
| Mean | 37.8 ± 12.9 | 39.8 ± 14.0 | 40.4 ± 11.4 | 36.4 ± 14.4 | 38.3 ± 13.5 |
| Sex: Female, Male(Participants) | Arm C (Control): No Prophylaxis, Then Emicizumab | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 18 | 36 | 35 | 63 | 152 |
| Ethnicity (NIH/OMB)(Participants) | Arm C (Control): No Prophylaxis, Then Emicizumab | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 5 | 7 | 16 |
| Not Hispanic or Latino | 17 | 32 | 30 | 53 | 132 |
| Unknown or Not Reported | 1 | 0 | 0 | 3 | 4 |
| Race (NIH/OMB)(Participants) | Arm C (Control): No Prophylaxis, Then Emicizumab | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 6 | 10 | 12 | 32 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 3 | 3 | 1 | 1 | 8 |
| White | 11 | 24 | 20 | 47 | 102 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 4 | 3 | 9 |
| Number of Participants with <9 or ≥9 Bleeds in the Last 24 Weeks Prior to Study Entry(Participants) | Arm C (Control): No Prophylaxis, Then Emicizumab | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | Total |
|---|---|---|---|---|---|
| Less Than (<) 9 Bleeds | 4 | 9 | 5 | 53 | 71 |
| Greater Than or Equal To (≥) 9 Bleeds | 14 | 27 | 30 | 10 | 81 |
| Number of Target Joints in the Last 24 Weeks Prior to Study Entry(target joints) | Arm C (Control): No Prophylaxis, Then Emicizumab | Arm A: Emicizumab 1.5 mg/kg QW | Arm B: Emicizumab 3 mg/kg Q2W | Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | Total |
|---|---|---|---|---|---|
| Mean | 2.2 ± 1.4 | 2.1 ± 1.4 | 2.2 ± 1.7 | 1.0 ± 1.6 | 1.7 ± 1.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Sep 2017, 11 months.
Results were first posted in Nov 2018, 1 year 1 month after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 11 months is below that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emicizumab